Loading…
Based on limited metadata, Invitrx Therapeutics Inc. received an FDA Warning Letter on March 16, 2020, regarding biologics products. Without access to the full letter text or subject line details, the specific nature of the violations cannot be determined from the available information. The warning was issued under FDA's biologics regulatory authority, which typically covers therapeutic proteins, vaccines, and cell/gene therapy products. To understand the particular compliance issues cited, the complete Warning Letter would need to be reviewed.